CPT code 52250 denotes cystoscopic delivery of a radioactive agent into the bladder to treat bladder cancer, performed with direct endoscopic visualization and potential biopsy or fulguration of suspicious lesions. Nationally, this code captures a specialized urologic oncology procedure used for intravesical radiation therapy as part of bladder-sparing management strategies. Accurate coding supports appropriate tracking of oncologic care, reimbursement for facility and professional components, and quality measurement for bladder cancer interventions.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise reference to how this procedure is described clinically, typical sites of service, and common modifiers that may appear on claims. Readers will find benchmarks and coding context relevant to billing and revenue cycle operations, a summary of clinical indications tied to bladder malignancy, and notes on documentation elements commonly needed to support medical necessity.

This material is intended for coding professionals, revenue cycle staff, and clinical leaders seeking a clear, national-level overview of CPT code 52250, its clinical role in bladder cancer care, and the coding considerations that affect claim processing and policy alignment.